看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
# a! C, Y' M5 Z
- }' C, E: n( h' P- u3 L& `+ m' I% S0 y: d3 n
Currently available feasibility data for possible combination strategies.
2 t& {. h- O& `9 B; T3 h————————————————————————————————; J7 Z- D5 I+ r
Combination Feasibility according to preliminary data 9 H- `9 y: l( h, V% o
——————————————————————————————————
9 {2 v ~6 r V) M$ M. WBevacizumab + sorafenib Yes, reduced dose
2 R' R, `/ f/ }Bevacizumab + sunitinib† No
2 f+ u5 Z8 |' Y6 j6 w: W! i" bBevacizumab + temsirolimus Yes 4 Y, T/ E: x& A" {+ f
Bevacizumab + everolimus Yes ! T8 X& j# A) i7 }+ [. o& ?! ]
Sorafenib + sunitinib ? 2 ~$ @! |! y W, k9 m
Sorafenib + temsirolimus Yes, reduced dose
9 H/ }. c9 x8 `+ X7 YSorafenib + everolimus Yes, reduced dose
/ D4 G# @, T YSunitinib + temsirolimus† No
3 |7 }% X+ d4 MSunitinib + everolimus ?
7 Y5 v J+ H7 ~4 PTemsirolimus + everolimus ? 3 w9 E- ~* O3 u8 M
————————————————————/ d% ] s# d. h- V* v
†Led to US FDA warning.
" u+ V! i1 M$ {& t1 y( M?: As yet unattempted combination.% u- k8 B$ Z7 H: T) S* T/ O
|
显身卡
6 R' ?' |& X6 B1 [
